ArticleTargeted oncology2026
A Podcast on Osimertinib After CRT in Unresectable Stage III EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC): Current and Future Perspectives.
Article in Targeted oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) disease biology may differ from EGFR-wild type NSCLC, with an increased risk of distant metastases in unresectable stage III EGFRm NSCLC. Osimertinib is an established first treatment for patients with EGFRm advanced NSCLC, effectively treating EGFRm tumours. The phase III LAURA study, which assessed the efficacy and safety of osimertinib for patients with locally advanced, unresectable stage III EGFRm NSCLC who completed chemoradiotherapy (CRT) without disease progression, demonstrated a statistically significant improvement with osimertinib in progression-free survival (PFS), with a median PFS of 39.1 months, versus 5.6 months with placebo. The safety profile was as expected based on the known profiles of osimertinib and CRT. On the basis of the LAURA results, osimertinib has now been approved for the treatment of unresectable stage III EGFRm NSCLC. Given the implementation of the LAURA regimen in multiple countries, this podcast highlights the potential challenges that must be considered by healthcare professionals when administering osimertinib in clinical practice, and how these may be mitigated. Considerations of the impact of the 'treat-to-progression' approach, a paradigm shift for the treatment of stage III unresectable NSCLC, and patient-centred care, including the importance of shared decision-making, will also be discussed. Overall, continuous systemic treatment post-CRT may be key to improving long-term outcomes and represents a mindset shift for both healthcare professionals and patients. Therefore, we may need to consider unresectable stage III EGFRm NSCLC as a chronic disease, requiring long-term treatment to maintain suppression of disease.The podcast and transcript can be viewed below the abstract of the online version of the manuscript. Alternatively, the podcast can be downloaded here: https://doi.org/ https://doi.org/10.6084/m9.figshare.33191613 . Supplementary file1 (MP4 306769 KB).
Identifiers
42867814What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.